Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Drug Coverage, Costs Under Scrutiny

Feb 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

US Pharma Challenges 2014

Jan 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.

Pharma Challenges for 2014

Jan 1, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing

FDA Pursues Delicate Balancing Act

Dec 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Clinical Trial Sponsors Struggle with Data Disclosure Requirements

Policies to widen access to patient level data from clinical trials are gaining traction, despite strong opposition from research sponsors that such initiatives will undermine patient privacy and incentives for new drug development.
Nov 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

Transparency Troubles for Pharma

Nov 1, 2013

High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.

The Brand–Generic Wars Heat Up

Oct 10, 2013

As insurers, payers, and drug plan operators eye increased generic drug use as key to cutting healthcare costs, pharma companies are ramping up efforts to delay marketing of copycat products.

Brand-Generic Wars Heat Up

Oct 1, 2013

Tension mounts over biosimilars, co-pay coupons, trade, and testing.

Biopharma Innovation in Trouble?

Sep 1, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

ADVERTISEMENT

Click here